2024-10-19 - Analysis Report
## Gilead Sciences Inc (GILD) Stock Analysis Report

**Company Overview:** Gilead Sciences Inc. is a biopharmaceutical company focused on developing and commercializing innovative medicines for life-threatening diseases.

**1. Performance Comparison:**

* **Cumulative Return (GILD):** -9.85%
* **Cumulative Return (S&P 500, VOO):** 136.97%
* **Performance Gap:** -146.82% (Relative Gap: 5.63%)

Gilead Sciences Inc. has significantly underperformed the S&P 500 over the period analyzed. The stock's cumulative return is significantly lower than the benchmark index. The relative gap indicates that GILD's performance has been worse than the S&P 500 for most of the historical period. 

**2. Recent Price Movements:**

* **Closing Price:** $87.36
* **5-Day Moving Average:** $85.99
* **20-Day Moving Average:** $84.65
* **60-Day Moving Average:** $79.99

The stock price is currently above all three moving averages, suggesting a potential upward trend. However, the relatively small difference between the price and the 5-day moving average indicates short-term volatility.

**3. Technical Indicators:**

* **RSI:** 70.01 (Overbought)
* **PPO:** -0.03 (Slight Bearish)
* **Delta_Previous_Relative_Divergence:** -0.63 (Short-Term Downward Trend)
* **Expected Return:** 0.0% (Maximum 5-year expected return compared to S&P 500, VOO)

The RSI is currently in the overbought zone, indicating potential for a short-term pullback. The negative PPO suggests a weakening momentum. The negative Delta_Previous_Relative_Divergence further indicates a short-term downward trend. The expected return is currently zero, suggesting the potential for a volatile period.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-08 | 1.29 | 6.95 B$ |
| 2024-05-08 | -3.34 | 6.69 B$ |
| 2023-11-07 | 1.75 | 7.05 B$ |
| 2023-08-04 | 0.84 | 6.60 B$ |
| 2024-08-08 | 0.84 | 6.60 B$ |

The most recent earnings report (2024-08-08) showed an EPS of 1.29, exceeding analyst expectations.  Revenue also slightly exceeded expectations, demonstrating strong performance. While the previous quarter had a loss, overall, the company has been showing some positive signs in recent earnings.

**5. News and Recent Issues:**

* **Recent Market Outlook for GILD:** Gilead Sciences is facing challenges in its core HIV business due to generic competition, but there is potential for growth in new areas like oncology, inflammation and immunology. The company's pipeline of new drugs holds promise for future growth.
* **Analyst Opinions and Performance Highlights:** While GILD's stock has underperformed the market, analysts are generally bullish on the company's future due to its strong financial position, solid pipeline of new drugs, and focus on diversifying its business. 

**6. Overall Analysis:**

Gilead Sciences Inc. presents a mixed picture. While recent earnings have been positive, and analysts hold a bullish outlook, the stock's long-term performance has been weak. The company is facing challenges in its core HIV business but has opportunities in other areas. The stock is currently showing some positive technical signals, but it is essential to monitor its performance closely, particularly in the context of its recent volatility.

**7. Recommendations:**

* **Short-term:** Given the overbought RSI and negative Delta_Previous_Relative_Divergence, short-term investors may consider waiting for a pullback before entering a position.
* **Long-term:** Long-term investors might find Gilead Sciences appealing due to its strong financial position, diversified business, and potential for growth in new markets. However, careful monitoring of the company's pipeline progress is crucial.

**Disclaimer:** This analysis is for informational purposes only and should not be considered financial advice. Please consult with a qualified financial professional before making any investment decisions. 
